Harmone Receptor-positive, HER2-negative Early Breast Cancer Adjuvant Use of Abemaciclib nearly halves the Incidence of Distant Metastases

被引：0
|
作者：
Ruedesheim, Sabine M.
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [42] Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
    Gaia Griguolo
    Maria Vittoria Dieci
    Laia Paré
    Federica Miglietta
    Daniele Giulio Generali
    Antonio Frassoldati
    Luigi Cavanna
    Giancarlo Bisagni
    Federico Piacentini
    Enrico Tagliafico
    Katia Cagossi
    Guido Ficarra
    Aleix Prat
    Pierfranco Conte
    Valentina Guarneri
    npj Breast Cancer, 7
  • [43] Evolving treatment patterns in hormone receptor-positive, HER2-negative metastatic breast cancer
    Lankford, M. L.
    Britton, S. L.
    Buettner, A. D.
    Scharf, M.
    Tiscione, B.
    Willey, J. P.
    Mahtani, R. L.
    CANCER RESEARCH, 2019, 79 (04)
  • [44] Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer
    Niu, Nan
    Xue, Jinqi
    Qiu, Fang
    Chen, Guanglei
    Gu, Xi
    He, Guijin
    Cao, Shuo
    Yu, Xiaopeng
    Xu, Yongqing
    Yin, Jianqiao
    Han, Sijia
    Han, Ye
    Tang, Meiyue
    Zhao, Yafei
    Zheng, Ran
    Zheng, Xinyu
    Xu, Hong
    Liu, Caigang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer
    I. Nederlof
    S. Hajizadeh
    F. Sobhani
    S. E. A. Raza
    K. AbdulJabbar
    R. Harkes
    M. J. van de Vijver
    R. Salgado
    C. Desmedt
    M. Kok
    Y. Yuan
    H. M. Horlings
    npj Breast Cancer, 8
  • [46] Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
    Griguolo, Gaia
    Dieci, Maria Vittoria
    Pare, Laia
    Miglietta, Federica
    Generali, Daniele Giulio
    Frassoldati, Antonio
    Cavanna, Luigi
    Bisagni, Giancarlo
    Piacentini, Federico
    Tagliafico, Enrico
    Cagossi, Katia
    Ficarra, Guido
    Prat, Aleix
    Conte, Pierfranco
    Guarneri, Valentina
    NPJ BREAST CANCER, 2021, 7 (01)
  • [47] The natural history of untreated estrogen receptor-positive, Her2-negative invasive breast cancer
    Rojas, Kristin E.
    Manasseh, Donna-Marie
    Rojas, Mary
    Mattocks, Andrea
    Portnow, Leah
    Kantharia, Sarah
    Zelenko, Natalie
    Giuliano, Christina
    Borgen, Patrick, I
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 182 (01) : 79 - 83
  • [48] Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer
    Rugo, Hope S.
    Haltner, Anja
    Zhan, Lin
    Tran, Anh
    Bananis, Eustratios
    Hooper, Becky
    Mitra, Debanjali
    Cameron, Chris
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (06) : 457 - 467
  • [49] Abemaciclib and endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: A real-world UK multicentre experience
    Battisti, Nicolo Matteo Luca
    Morrison, Laura
    Nash, Tamsin
    Senthivel, Nishanti
    Kestenbaum, Samantha
    Begum, Parvin
    Obeid, Mariam
    Hayhurst, William
    Yang, Dorothy
    Gafoor, Shafiah
    Brown, Caroline
    Rehman, Farah
    Kenny, Laura
    Hatcher, Olivia
    Susan, Susan
    Williams, Jennet
    Brown, Anna
    Rozati, Hamoun
    Alexandros, Alexandros
    Sawyer, Elinor
    Gousis, Charalampos
    Karapanagiotou, Eleni
    Rigg, Anna
    Rapti, Kleopatra
    Roylance, Rebecca
    Beresford, Mark
    Gee, Abigail L.
    Konstantis, Apostolos
    King, Judy
    Nathan, Mark
    Spurrell, Emma
    Pearce, Mark
    Bradwell, Dane
    Denton, Arshi
    Swain, Kate
    McGrath, Sophie
    Allen, Mark
    Ring, Alistair
    Johnston, Stephen
    Raja, Fharat
    CANCER RESEARCH, 2022, 82 (04)
  • [50] Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer
    Kubo, Makoto
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
12345